Mechanisms of action and resistance of older and newer fluoroquinolones

Clinical Infectious Diseases

Volumn 31, Issue SUPPL. 2, 2000, Pages

  Hooper, D C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CONFERENCE PAPER; DNA REPLICATION; DRUG MECHANISM; GENE OVEREXPRESSION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; ENZYME INHIBITORS; ESCHERICHIA COLI; FLUOROQUINOLONES; HUMANS; MUTATION; STAPHYLOCOCCUS AUREUS;

EID: 0034454247     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314056     Document Type: Conference Paper

References (32)

1. DNA gyrase, topoisomerase IV, and the 4-quinolones
2. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones
3. DNA topoisomerases
4. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance
5. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication
6. Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli
7. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex
8. Escherichia coli K-12 mutants resistant to nalidixic acid: Genetic mapping and dominance studies
9. The mode of action of 4-quinolones and possible mechanisms of resistance
10. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli
11. Topoisomerase IV is a target of quinolones in Escherichia coli
12. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of parE gene encoding a subunit of topoisomerase IV
13. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
14. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus
15. Quinolone resistance mutations in topoisomerase IV: Relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus
16. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases
17. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
18. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
19. Mechanisms and frequency of resistance to gatifloxacin in comparison with ciprofloxacin in Staphylococcus aureus
20. Mechanisms of quinolone resistance
21. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification, and differential inhibition by fluoroquinolones
22. Primary targets of fluoroquinolones in Streptococcus pneumoniae
23. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
24. Relationship between mutations in the coding and promoter regions of the nor A genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICs of norfloxacin for these strains
25. Quinolone resistance mediated by nor A: Physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome
26. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus
27. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA
28. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the nor A transformant of Staphylococcus aureus
29. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
30. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
31. Nucleotide sequence and characterization of the Staphylococcus aureus nor A gene, which confers resistance to quinolones
32. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus